Analysts at SunTrust Robinson Humphrey initiated coverage on Sage Therapeutics, Inc. SAGE with a Buy rating.
The target price for Sage Therapeutics is set to $67.
Sage Therapeutics' shares rose 5.75% to close at $40.45 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in